Document is current

Article History

Accepted: 15 August 2024

First Online: 22 August 2024

Declarations

:

: The study protocol received ethical approval from the research involving animal of Nanchang Royo Biotech, Ltd. (Animal Ethics: RYE2021092101), and the Medical Ethics Committee of Nanchang Reproductive Hospital (Reproductive Hospital Affiliated to Jiangxi University of Traditional Chinese Medicine) (Clinical Ethics: 2021005), and registered in the Chinese Clinical Trial Registry (Registration number: ChiCTR2100051730). All animal studies conducted in this research were approved and carried out in strict adherence to the guidelines for the use of experimental animals set forth by the Committee on the Use of Live Animals in Teaching and Research at the University of Nanchang. Additionally, all authors of this study affirm that the tumor burden in the animals did not exceed the recommended dimensions outlined by ethical standards. Furthermore, animals were appropriately anaesthetized and euthanized using accepted methods and techniques, ensuring humane and ethical intervention throughout the experimental procedures. These measures underscore our commitment to upholding animal welfare and complying with established ethical protocols in scientific research. All clinical patients who participated in this study were thoroughly informed about the potential effects and implications of the research. Before commencing the study, each patient provided their informed consent by signing a document that outlined the details of the study, including its purpose, procedures, potential risks, and benefits. This informed consent process ensured that patients had a clear understanding of what their participation entailed and gave them the opportunity to ask questions or seek further clarification before making an informed decision to participate<b>.</b>

: The authors declare no competing interests.